Autor: Merkelbach, Matthias - Katalog zbiorów Biblioteki Wyższej Szkoły Bankowej we Wrocławiu

Skocz do pozycji: 1 1.

Tytuł :: Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC.
Autorzy :: Saleh MM; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheel AH; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Ulmer B; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Buettner R; Lung Cancer Group Cologne, Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .; Pokaż więcej
Źródło :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Jan; Vol. 17 (1), pp. 76-88. Date of Electronic Publication: 2021 Sep 30.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.
Autorzy :: Schaufler D; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Ast DF; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; Mildred Scheel School of Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tumbrink HL; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Abedpour N; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne, Cologne, Germany.
Maas L; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Schwäbe AE; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Spille I; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Lennartz S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Fassunke J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Aldea M; Department of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Besse B; Department of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Planchard D; Department of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Nogova L; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Michels S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Kobe C; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, Germany.
Persigehl T; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Diagnostic and Interventional Radiology, Cologne, Germany.
Westphal T; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Koleczko S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Fischer R; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Weber JP; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Altmüller J; Cologne Center for Genomics, University of Cologne, Cologne, Germany.
Thomas RK; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.; DKFZ, German Cancer Research Center, German Cancer Consortium (DKTK), Heidelberg, Germany.
Merkelbach-Bruse S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Gautschi O; University of Bern and Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Mezquita L; Medical Oncology Department, Hospital Clinic, Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Büttner R; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Wolf J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Peifer M; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Brägelmann J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany. .; Mildred Scheel School of Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne, Cologne, Germany. .
Scheffler M; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany. matthias..
Sos ML; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany. .; University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Molecular Medicine Cologne, Cologne, Germany. .; Pokaż więcej
Źródło :: NPJ precision oncology [NPJ Precis Oncol] 2021 Dec 17; Vol. 5 (1), pp. 102. Date of Electronic Publication: 2021 Dec 17.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
Autorzy :: Diana Schaufler
David F. Ast
Hannah L. Tumbrink
Nima Abedpour
Lukas Maas
Ayla E. Schwäbe
Inga Spille
Stefanie Lennartz
Jana Fassunke
Mihaela Aldea
Benjamin Besse
David Planchard
Lucia Nogova
Sebastian Michels
Carsten Kobe
Thorsten Persigehl
Theresa Westphal
Sophia Koleczko
Rieke Fischer
Jan-Phillip Weber
Janine Altmüller
Roman K. Thomas
Sabine Merkelbach-Bruse
Oliver Gautschi
Laura Mezquita
Reinhard Büttner
Jürgen Wolf
Martin Peifer
Johannes Brägelmann
Matthias Scheffler
Martin L. Sos; Pokaż więcej
Temat :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :: npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Opis pliku :: electronic resource
Relacje :: https://doaj.org/toc/2397-768X
Dostęp URL :: https://doaj.org/article/2fe94ce5763c49248add719a2c82fe60
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
Autorzy :: Thelen, Martin
Wennhold, Kerstin
Lehmann, Jonas
Garcia-Marquez, Maria
Klein, SebastianAff2, Aff3
Kochen, Elena
Lohneis, Philipp
Lechner, Axel
Wagener-Ryczek, Svenja
Plum, Patrick SvenAff2, Aff3, Aff5
Velazquez Camacho, Oscar
Pfister, David
Dörr, Fabian
Heldwein, Matthias
Hekmat, Khosro
Beutner, Dirk
Klussmann, Jens Peter
Thangarajah, Fabinshy
Ratiu, Dominik
Malter, Wolfram
Merkelbach-Bruse, Sabine
Bruns, Christiane JosephineAff1, Aff5
Quaas, Alexander
von Bergwelt-Baildon, MichaelAff1, Aff11, Aff12
Schlößer, Hans A.Aff1, Aff5; Pokaż więcej
Źródło :: npj Precision Oncology. 5(1)
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
Autorzy :: Martin Thelen
Kerstin Wennhold
Jonas Lehmann
Maria Garcia-Marquez
Sebastian Klein
Elena Kochen
Philipp Lohneis
Axel Lechner
Svenja Wagener-Ryczek
Patrick Sven Plum
Oscar Velazquez Camacho
David Pfister
Fabian Dörr
Matthias Heldwein
Khosro Hekmat
Dirk Beutner
Jens Peter Klussmann
Fabinshy Thangarajah
Dominik Ratiu
Wolfram Malter
Sabine Merkelbach-Bruse
Christiane Josephine Bruns
Alexander Quaas
Michael von Bergwelt-Baildon
Hans A. Schlößer; Pokaż więcej
Temat :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :: npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Opis pliku :: electronic resource
Relacje :: https://doaj.org/toc/2397-768X
Dostęp URL :: https://doaj.org/article/4edee7d56ead4b1585567524e79d56a7
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study
Autorzy :: Bauerle, Michael
Besselmann, Michael
Büttner, T
Dem, Petra
Diekmann, Jens
Dietzel, Joanna
Dziewas, Rainer
Ehrlich, Sven
Evens, Annette
Gahn, Georg
Günther, Albrecht
Hamann, Gerhard F
Hartmann, Andreas
Harvey, Karen Louise
Heidenreich, Fedor
Helberg, T
Hobohm, Carsten
Hoffmann, F
Hoffmann, Olaf
Jungehulsing, Gerhard J
Kampschulte, Eva-Maria
Kraft, Peter
Krogias, Christos
Leinisch, Elke
Maschke, Matthias
Merkelbach, Stefan
Muehler, Johannes
Niehaus, Ludwig
Nören, Gesa
Oschmann, P
Palm, Frederick
Petzold, Gabor C
Pfeiler, Larissa
Pfeilschifter, Waltraud
Prince, Marie
Ringleb, Peter
Rosenkranz, Michael
Royl, Georg
Schnabel, Renate B
Schurig, Johannes
Steinbrecher, A
Stingele, Robert
Tanislav, Christian
Tyler, Louise
Urbanek, Christian
Haeusler, Karl Georg; Pokaż więcej
Źródło :: In The Lancet Neurology June 2021 20(6):426-436
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Informacja :: Dostęp do tej pozycji wymaga zalogowania się.
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Autorzy :: Kron A; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Scheffler M; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Heydt C; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Ruge L; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Schaepers C; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Eisert AK; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Riedel R; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Nogova L; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Fischer RN; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Michels S; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Abdulla DSY; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Koleczko S; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Fassunke J; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Schultheis AM; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Kron F; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany; FOM University of Applied Sciences, Essen, Germany.
Ueckeroth F; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Wessling G; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Sueptitz J; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Beckers F; Network Genomic Medicine, Cologne, Germany; Department of Thoracic Surgery, St. Vinzenz-Hospital Cologne, Cologne, Germany.
Braess J; Network Genomic Medicine, Cologne, Germany; Department of Hematology and Oncology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany.
Panse J; Network Genomic Medicine, Cologne, Germany; Department of Internal Medicine IV, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital RWTH Aachen, Aachen, Germany.
Grohé C; Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Evangelische Lungenklinik Berlin, Berlin, Germany.
Hamm M; Network Genomic Medicine, Cologne, Germany; Department of Pneumology and Respiratory Medicine, Helios Medical Center of Hildesheim, Hildesheim, Germany.
Kabitz HJ; Network Genomic Medicine, Cologne, Germany; Department of Internal Medicine II, Clinic of Konstanz, Konstanz, Germany.
Kambartel K; Network Genomic Medicine, Cologne, Germany; Department of Thoracic Oncology and Interventional Bronchology, Hospital Bethanien Moers, Moers, Germany.
Kaminsky B; Network Genomic Medicine, Cologne, Germany; Department of Pneumonology and Allergology, Hospital Bethanien Solingen, Solingen, Germany.
Krueger S; Network Genomic Medicine, Cologne, Germany; Department of Pneumonology, Florence-Nightingale Hospital Düsseldorf, Düsseldorf, Germany.
Schulte C; Network Genomic Medicine, Cologne, Germany; Joint Private Practice for Hematology/Oncology, Dortmund, Germany.
Lorenz J; Network Genomic Medicine, Cologne, Germany; Department of Pneumology, Hospital Luedenscheid, Luedenscheid, Germany.
Lorenzen J; Network Genomic Medicine, Cologne, Germany; Department of Pathology, Hospital Dortmund, Dortmund, Germany.
Meister W; Network Genomic Medicine, Cologne, Germany; Department of Thoracic Oncology and Interventional Bronchology, Helios Medical Center of Hildesheim, Hildesheim, Germany.
Meyer A; Network Genomic Medicine, Cologne, Germany; Department of Pulmonary Medicine, Maria Hilf Hospital GmbH, Moenchengladbach, Germany.
Kappes J; Network Genomic Medicine, Cologne, Germany; Department of Internal Medicine and Pneumology, Catholic Hospital Koblenz, Koblenz, Germany.
Reinmuth N; Network Genomic Medicine, Cologne, Germany; Department of Oncology, Asklepios Clinic Munich-Gauting, Munich-Gauting, Germany.
Schaaf B; Network Genomic Medicine, Cologne, Germany; Department of Respiratory Medicine and Infectious Diseases, Medical Center North of Dortmund, Dortmund, Germany.
Schulte W; Network Genomic Medicine, Cologne, Germany; Department of Pneumology and Allergology, GFO Clinic Bonn, Bonn, Germany.
Serke M; Network Genomic Medicine, Cologne, Germany; Department of Pneumology and Oncology, Evangelic Hospital Hamm, Hamm, Germany.
Buettner R; Network Genomic Medicine, Cologne, Germany; Institute of Pathology, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany.
Wolf J; Network Genomic Medicine, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University Hospital of Cologne, Cologne, Germany. Electronic address: .; Pokaż więcej
Źródło :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Apr; Vol. 16 (4), pp. 572-582. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji :: Journal Article
MeSH Terms :: Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Genetic Heterogeneity ; Humans ; Immunotherapy ; In Situ Hybridization, Fluorescence ; Mutation ; Proto-Oncogene Proteins c-met/genetics
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
Autorzy :: Gassa A; Department of Cardiothoracic Surgery, University of Cologne, Germany; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany. Electronic address: .
Fassunke J; Institute of Pathology, University of Cologne, Germany.
Schueten S; Department of Cardiothoracic Surgery, University of Cologne, Germany; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany; School of Medicine, University of Cologne, Germany.
Kuhlmann L; Department of Cardiothoracic Surgery, University of Cologne, Germany; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany; School of Medicine, University of Cologne, Germany.
Scherer M; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany; School of Medicine, University of Cologne, Germany.
Qien J; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.
Zhao Y; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.
Michel M; Institute of Zoology, University of Cologne, Germany.
Loeser H; Institute of Pathology, University of Cologne, Germany.
Wolf J; Department of Internal Medicine I, University of Cologne, Germany.
Buettner R; Institute of Pathology, University of Cologne, Germany.
Doerr F; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Heldwein M; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Hagmeyer L; Hospital Bethanien Solingen, Institute of Pneumology, University of Cologne, Solingen, Germany.
Frank K; Department of Internal Medicine III, University of Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, University of Cologne, Germany.
Quaas A; Institute of Pathology, University of Cologne, Germany.
Bruns C; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.
Hekmat K; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Weiss J; Department of Internal Medicine I, University of Cologne, Germany.
Wahlers T; Department of Cardiothoracic Surgery, University of Cologne, Germany.
Alakus H; Department of General, Visceral, and Cancer Surgery, University of Cologne, Germany.; Pokaż więcej
Źródło :: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2021 Jan; Vol. 151, pp. 91-96. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Circulating Tumor DNA*/genetics
Lung Neoplasms*/diagnosis
Lung Neoplasms*/genetics
Neoplasm Recurrence, Local*/genetics
Biomarkers, Tumor/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Mutation ; Polymerase Chain Reaction ; Prospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Was die neuen Kriterien für die Institute bedeuten. (German)
Autorzy :: Merkelbach, Matthias
Hören, Martin von; Pokaż więcej
Źródło :: Die Bank; 2020, Issue 10, p48-51, 4p
: Periodyk

Szczegóły Pełny tekst

Skocz do pozycji: 11 11.

Tytuł :: NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.
Autorzy :: Kirchner M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Glade J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Lehmann U; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Merkelbach-Bruse S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Hummel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Lehmann A; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Trautmann M; Institute of Pathology, University Hospital Münster, Münster, Germany.
Kumbrink J; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Jung A; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Dietmaier W; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Endris V; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Ploeger C; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Evert M; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Horst D; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Kreipe H; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Kirchner T; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Wardelmann E; Institute of Pathology, University Hospital Münster, Münster, Germany.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Weichert W; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Dietel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.; Quality Assurance Initiative in Pathology (QuiP), Berlin, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Pfarr N; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.; Pokaż więcej
Źródło :: Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2020 Aug; Vol. 59 (8), pp. 445-453. Date of Electronic Publication: 2020 May 09.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Biomarkers, Tumor/*genetics
Genetic Testing/*methods
Neoplasms/*genetics
Oncogene Proteins, Fusion/*genetics
RNA-Seq/*methods
Receptor Tyrosine Kinase-like Orphan Receptors/*genetics
Genetic Testing/standards ; Humans ; In Situ Hybridization, Fluorescence/methods ; Neoplasms/diagnosis ; RNA-Seq/standards ; Sensitivity and Specificity ; Tissue Preservation/methods
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment.
Autorzy :: Nogova, Lucia (AUTHOR)
Mattonet, Christian (AUTHOR)
Scheffler, Matthias (AUTHOR)
Taubert, Max (AUTHOR)
Gardizi, Masyar (AUTHOR)
Sos, Martin L. (AUTHOR)
Michels, Sebastian (AUTHOR)
Fischer, Rieke N. (AUTHOR)
Limburg, Meike (AUTHOR)
Abdulla, Diana S.Y. (AUTHOR)
Persigehl, Thorsten (AUTHOR)
Kobe, Carsten (AUTHOR)
Merkelbach‐Bruse, Sabine (AUTHOR)
Franklin, Jeremy (AUTHOR)
Backes, Heiko (AUTHOR)
Schnell, Roland (AUTHOR)
Behringer, Dirk (AUTHOR)
Kaminsky, Britta (AUTHOR)
Eichstaedt, Martina (AUTHOR)
Stelzer, Christoph (AUTHOR); Pokaż więcej
Źródło :: Cancer Medicine. Jul2020, Vol. 9 Issue 14, p4991-5007. 17p.
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 13 13.

Tytuł :: Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
Autorzy :: Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: .
Endris V; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Budczies J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Merkelbach-Bruse S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany.
Dietmaier W; Institute of Pathology, University Regensburg, Regensburg, Germany.
Pfarr N; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Siebolts U; Institute of Pathology, University Hospital Halle, Halle, Germany.
Hummel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Herold S; Institute of Pathology, University Hospital Dresden, Dresden, Germany.
Andreas J; Institute of Hematopathology, Hamburg, Germany.
Zoche M; Institute of Pathology, University Hospital Zurich, Zurich, Switzerland.
Tögel L; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany.
Rempel E; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Maas J; Quality in Pathology (QuIP), Berlin, Germany.
Merino D; Friends of Cancer Research (FoCR), Washington, District of Columbia.
Stewart M; Friends of Cancer Research (FoCR), Washington, District of Columbia.
Zaoui K; Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany.
Schlesner M; Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Glimm H; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT Dresden) and University Hospital Carl Gustav Carus, Dresden, and Translational Functional Cancer Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK), Dresden, Germany.
Fröhling S; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Allen J; Friends of Cancer Research (FoCR), Washington, District of Columbia.
Horst D; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Baretton G; Institute of Pathology, University Hospital Dresden, Dresden, Germany.
Wickenhauser C; Institute of Pathology, University Hospital Halle, Halle, Germany.
Tiemann M; Institute of Hematopathology, Hamburg, Germany.
Evert M; Institute of Pathology, University Regensburg, Regensburg, Germany.
Moch H; Institute of Pathology, University Hospital Zurich, Zurich, Switzerland.
Kirchner T; Institute of Pathology, Ludwig-Maximilians University (LMU), Munich, Germany.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Jung A; Institute of Pathology, Ludwig-Maximilians University (LMU), Munich, Germany.
Haller F; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany.
Weichert W; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Dietel M; Quality in Pathology (QuIP), Berlin, Germany.; Pokaż więcej
Źródło :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 Jul; Vol. 15 (7), pp. 1177-1189. Date of Electronic Publication: 2020 Feb 29.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Lung Neoplasms*/genetics
Biomarkers, Tumor/genetics ; Humans ; Mutation ; Reference Standards ; Whole Exome Sequencing
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment
Autorzy :: Lucia Nogova
Christian Mattonet
Matthias Scheffler
Max Taubert
Masyar Gardizi
Martin L. Sos
Sebastian Michels
Rieke N. Fischer
Meike Limburg
Diana S.Y. Abdulla
Thorsten Persigehl
Carsten Kobe
Sabine Merkelbach‐Bruse
Jeremy Franklin
Heiko Backes
Roland Schnell
Dirk Behringer
Britta Kaminsky
Martina Eichstaedt
Christoph Stelzer
Martina Kinzig
Fritz Sörgel
Yingying Tian
Lisa Junge
Ahmed A. Suleiman
Sebastian Frechen
Dennis Rokitta
Dongsheng Ouyang
Uwe Fuhr
Reinhard Buettner
Jürgen Wolf; Pokaż więcej
Temat :: FDG‐PET
KRAS mutation
non‐small‐cell lung cancer
pharmacodynamics
pharmacokinetics
Phase‐I trial
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :: Cancer Medicine, Vol 9, Iss 14, Pp 4991-5007 (2020)
Opis pliku :: electronic resource
Relacje :: https://doaj.org/toc/2045-7634
Dostęp URL :: https://doaj.org/article/04f6918ff70742839866e3f4fa056a57
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 15 15.

Tytuł :: Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Autorzy :: Scheffler M; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Holzem A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Kron A; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Nogova L; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Ihle MA; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
von Levetzow C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fassunke J; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wömpner C; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Bitter E; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Koleczko S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Abdulla DSY; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Michels S; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Fischer R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Riedel R; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Weber JP; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Westphal T; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany.
Gerigk U; GFO Clinics Bonn, Marien-Hospital Bonn, Bonn, Germany.
Kern J; KWM Missio Clinic, Würzburg, Germany.
Kaminsky B; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Randerath W; Bethanien Hospital Solingen, Clinic for Pulmonology and Allergology, Solingen, Germany.
Kambartel KO; Bethanien Hospital Moers, Lung Center, Moers, Germany.
Merkelbach-Bruse S; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Büttner R; University of Cologne, Cologne Institute of Pathology, Cologne, Germany.
Wolf J; University Hospital of Cologne, Lung Cancer Group Cologne, Department I of Internal Medicine, Cologne, Germany. Electronic address: .; Pokaż więcej
Źródło :: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Jun; Vol. 144, pp. 40-48. Date of Electronic Publication: 2020 Apr 24.
Typ publikacji :: Journal Article
MeSH Terms :: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Kelch-Like ECH-Associated Protein 1 ; MAP Kinase Kinase 1/genetics ; Mutation ; NF-E2-Related Factor 2 ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.
Autorzy :: Pfarr N; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Kirchner M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Lehmann U; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Leichsenring J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Merkelbach-Bruse S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Glade J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Hummel M; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Stögbauer F; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Lehmann A; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Trautmann M; Gerhard-Domagk-Institute of Pathology, and Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Kumbrink J; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Jung A; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Dietmaier W; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Endris V; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Evert M; Institute of Pathology, University Hospital Regensburg, Regensburg, Germany.
Horst D; Institute of Pathology, Charité University Hospital, Berlin, Germany.
Kreipe H; Institute of Pathology, University Hospital Hannover, Hannover, Germany.
Kirchner T; Institute of Pathology, Ludwig Maximilian University (LMU), Munich, Germany.
Wardelmann E; Gerhard-Domagk-Institute of Pathology, and Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Lassen U; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Büttner R; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Weichert W; Institute of Pathology, Technical University Munich (TUM), Munich, Germany.
Dietel M; Quality Initiative in Pathology (QuiP), Berlin, Germany.
Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Pokaż więcej
Źródło :: Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2020 Mar; Vol. 59 (3), pp. 178-188. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Biomarkers, Tumor*
Genetic Testing*/methods
High-Throughput Nucleotide Sequencing*/methods
High-Throughput Nucleotide Sequencing*/standards
Receptors, Nerve Growth Factor/*genetics
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Clinical Decision-Making ; Disease Management ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Infant ; Male ; Middle Aged ; Neoplasms/diagnosis ; Neoplasms/genetics ; Neoplasms/metabolism ; Receptors, Nerve Growth Factor/metabolism ; Reproducibility of Results ; Workflow ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Autorzy :: Riedel R; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Michels S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Heydt C; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Siemanowski J; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Kobe C; Department for Nuclear Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Bunck A; Department for Radiology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Schäfer S; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Fischer RN; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Abdulla DSY; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Nogová L; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Koleczko S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany.
Merkelbach-Bruse S; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Büttner R; Institute of Pathology, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Germany. Electronic address: .; Pokaż więcej
Źródło :: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2019 Jul; Vol. 133, pp. 20-22. Date of Electronic Publication: 2019 May 06.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Adenocarcinoma of Lung/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Mutation/*genetics
Proto-Oncogene Proteins c-met/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adenocarcinoma of Lung/genetics ; Biomarkers, Tumor/genetics ; Carcinogenesis/genetics ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Amplification ; Humans ; Lung Neoplasms/genetics ; Middle Aged ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Autorzy :: Michels S; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Massutí B; Department of Oncology, Alicante University Hospital-ISABIAL, Alicante, Spain.
Schildhaus HU; Institute of Pathology, University Hospital Goettingen, Göttingen, Germany and Targos Molecular Pathology, Kassel, Germany.
Franklin J; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Sebastian M; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Grohé C; Department of Pneumology, Protestant Lung Hospital Berlin, Berlin, Germany.
Rodriguez-Abreu D; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Abdulla DSY; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Bischoff H; Thoraxonkologie, Thoraxklinik, Heidelberg, Germany.
Brandts C; Department of Hematology and Oncology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
Carcereny E; Servei d'Oncologia Mèdica, Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, Carretera de Canyet, Badalona, Spain.
Corral J; Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; prior affiliation during the trial: Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Dingemans AC; Department for Oncology, Maastricht University Medical Center, Maastricht, Netherlands.
Pereira E; Spanish Lung Cancer Group, Barcelona, Spain.
Fassunke J; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Fischer RN; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Gardizi M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Heukamp L; Institute of Hematopatholgy Hamburg, Hamburg, Germany, and Lung Cancer Network NOWEL, Oldenburg, Germany.
Insa A; Hospital Clínico Universitario de Valencia, València, Spain.
Kron A; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Menon R; NEO New Oncology GmbH, Cologne, Germany.
Persigehl T; Department of Radiology, University Hospital Cologne, Cologne, Germany.
Reck M; Department for Thoracic Oncology, Airway Research Center North (ARCN), German Center for Lung Research, LungenClinic Grosshansdorf, Großhansdorf, Germany.
Riedel R; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rothschild SI; University Hospital Basel, Department Internal Medicine, Medical Oncology, Basel, Switzerland.
Scheel AH; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Schmalz P; Clinical Trials Centre Cologne (CTCC) Medical Faculty, University of Cologne, Cologne, Germany.
Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Limburg M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Provencio M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Spain.
Karachaliou N; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain.
Merkelbach-Bruse S; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Hellmich M; Institute of Medical Statistics and Computational Biology, University Hospital Cologne, Cologne, Germany.
Nogova L; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Büttner R; Lung Cancer Group Cologne, Institute of Pathology and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. Electronic address: .; Pokaż więcej
Źródło :: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Jul; Vol. 14 (7), pp. 1266-1276. Date of Electronic Publication: 2019 Apr 09.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Gene Rearrangement*
Brain Neoplasms/*drug therapy
Carcinoma, Non-Small-Cell Lung/*drug therapy
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/genetics ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Response Evaluation Criteria in Solid Tumors ; Survival Rate
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Autorzy :: Michels, Sebastian
Massuti, Bartomeu
Schildhaus, Hans-Ulrich
Franklin, Jeremy
Sebastian, Martin
Felip, Enriqueta
Grohe, Christian
Rodriguez-Abreu, Delvys
Abdulla, Diana S. Y.
Bischoff, Helge
Brandts, Christian
Carcereny, Enric
Corral, Jesus
Dingemans, Anne-Marie C.
Pereira, Eva
Fassunke, Jana
Fischer, Rieke N.
Gardizi, Masyar
Heukamp, Lukas
Insa, Amelia
Kron, Anna
Menon, Roopika
Persigehl, Thorsten
Reck, Martin
Riedel, Richard
Rothschild, Sacha I.
Scheel, Andreas H.
Scheffler, Matthias
Schmalz, Petra
Smit, Egbert F.
Limburg, Meike
Provencio, Mariano
Karachaliou, Niki
Merkelbach-Bruse, Sabine
Hellmich, Martin
Nogova, Lucia
Buettner, Reinhard
Rosell, Rafael
Wolf, Juergen; Pokaż więcej
Temat :: Lung cancer
Targeted treatment
ROS1
Crizotinib
TP53
ROS1 REARRANGEMENTS
ANAPLASTIC LYMPHOMA
ANTITUMOR-ACTIVITY
KINASE INHIBITION
TARGETING ROS1
ALK
ADENOCARCINOMA
CHEMOTHERAPY
MUTATIONS
FUSIONS
Źródło :: Journal of Thoracic Oncology, 14(7), 1266 - 1276. Elsevier Science

Szczegóły

Skocz do pozycji: 20 20.

Informacja :: Dostęp do tej pozycji wymaga zalogowania się.
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaBiblioteka WSB we Wrocławiu

Wyszukujesz frazę "Merkelbach, Matthias" wg kryterium: Autor

Źródło danych

Ogranicz do:

Dostawca treści

Typ dokumentu

Temat

Wydawca

Publikacja

Język